In an effort to understand the mechanisms of this conversion, we used isolated mitochondria from mouse liver and found that recombinant wild-type TRX1 could protect mitochondria from the apoptotic changes. In contrast, the mutant form of TRX1 alone elicited mitochondria-related apoptotic changes, including the mitochondrial permeability transition pore (mPTP) opening, loss of mitochondrial membrane potential, and cyto c release from mitochondria. These apoptotic effects were inhibited by cyclosporine A (CsA), indicating that mutant TRX1 targeted to mPTP. Alteration of TRX1 from its reduced form to oxidized form in vivo by 2,4-dinitrochlorobenzene (DNCB), a specific inhibitor of TRX reductase, also sensitized HepG 2 cells to As 2 O 3 -induced apoptosis. These data suggest that TRX1 plays a central role in regulating apoptosis by blocking cyto c release, and inactivation of TRX1 by either mutation or oxidization of the active site cysteines may sensitize tumor cells to As 2 O 3 -induced apoptosis.
Introduction
Arsenic trioxide (As 2 O 3 ) has been used clinically to effectively treat acute promyelocytic leukemia (APL) [1, 2] and other types of cancers [3, 4] . This success prompts studies to investigate the molecular mechanisms of action underlying the clinic effectiveness. As 2 O 3 might affect multiple intracellular signaling pathways, leading to alterations of cellular function. Subsequently, this compound was found to inhibit proliferation, or stimulate differentiation of tumor cells depending on the dosage and the cell system being used [5] . Increasing evidence has shown that As 2 O 3 inhibits growth of APL cell lines and some solid tumors by inducing apoptosis [6, 7, 2] . As 2 O 3 specifically induces degradation of a number of proteins including Bcl-2 and PML [8] [9] [10] , thereby overcoming drug resistance even in the relapsed cancers. Also, As 2 O 3 might target mitochondria to induce the opening of mitochondrial permeability transition pore (mPTP) [11, 12] , thus increasing intracellular reactive oxygen species (ROS) generation, which could then lead to Bax conformational changes and its translocation [13] . These changes in mitochondrial physiology would result in cytochrome c (cyto c) release and subsequent activation www.cell-research.com | Cell Research Changhai Tian et al. 459 npg of the apoptotic cascade. It is known that the intracellular redox system modulates both the anti-proliferative and pro-apoptotic effects of As 2 O 3 , and that the content of cellular GSH is negatively related to the sensitivity of tumor cells to As 2 O 3 [14] [15] [16] . The redox state in mammalian cells is primarily a consequence of the precise balance between the level of ROS and endogenous thiol buffers present in the cell, particularly, GSH and thioredoxin (TRX), which protect cells from oxidative damage [17] . The role of GSH in protecting cancer cells from As 2 O 3 -induced apoptosis is well-documented [18] . GSH binds arsenic to form a transient As (GS) 3 complex, thereby preventing the inactivation of intracellular enzymes responsible for redox homeostasis. Thioredoxin-1 (TRX1) is a 12 kD ubiquitous protein having a redox-active disulfide/dithiol within the conserved active site sequence (-Cys-Gly-Pro-Cys-). Oxidized TRX1 with a disulfide on its active site is reduced by NADPH-dependent thioredoxin reductase1 (TR1) [19, 20] to restore its functions. TRX1 plays an important role in regulating cell redox homeostasis and cell growth, differentiation, and apoptosis. TRX1 inhibits cell apoptosis in a manner similar to that of Bcl-2 in the transfected cells. The mechanism for the inhibition of apoptosis by TRX1 has been suggested, whereby TRX1 could bind to and inhibit apoptosis signal-regulating kinase 1 (ASK1), thus regulating the JNK/p38 signaling pathway in response to environmental stresses such as ROS [21, 22] . The dissociation between TRX1 and ASK1 induced by ROS leads to the activation of the ASK1/JNK signaling pathway, and subsequent increase of apoptosis [23, 24] . Although TRX is regarded as a critical molecule for modulating cell death, its role in determining cancer cell sensitivity towards As 2 O 3 has not been addressed. We thus attempted to investigate the role of cytoplasmic TRX1 in As 2 O 3 -induced apoptosis. Our results suggest that the redox status of TRX1 is important for modulating mitochondrial dependent apoptosis induced by As 2 O 3 . Inactivation of TRX1 either by mutation of the active site cysteine residues or by its oxidation enhances mitochondrial dependent apoptosis induced by As 2 O 3 . A better understanding of TRX1-mediated regulation of apoptosis elicited by As 2 O 3 may offer novel targets for treating As 2 O 3 -resistant tumors and combinative drug therapy.
Results

TRX1 is involved in As 2 O 3 -induced apoptosis in HepG 2 cells
We used a clinically relevant concentration of As 2 O 3 to treat the cell line HepG 2 at indicated times and then assayed apoptosis by examining Annexin V staining (data not shown) and the nuclear condensation. As 2 O 3 induced apoptosis in a time-dependent manner in HepG 2 cells (Figure 1A and 1B) . The optimal effect was obtained with 5 µM As 2 O 3 , with 45% cell death after 48 h treatment. Moreover, 5 µM As 2 O 3 induced the release of cyto c in HepG 2 cells in a time-dependent manner ( Figure 1C) , concomitant of the onset of caspase activation (data not shown). These results suggest that As 2 O 3 induced mitochondria-dependent apoptotic process as we described previously.
Human TRX1 acts as an important redox regulatory factor and plays a crucial role in drug-induced apoptosis [25] . We first examined the expression of TRX1 and found that the expression of TRX1 increased in a time-dependent manner in response to As 2 O 3 treatment ( Figure 1D ), suggesting that TRX1 is involved in As 2 O 3 -induced apoptosis. To confirm that TRX1 is functionally important in the sensitivity of HepG 2 cells to As 2 O 3 , we performed RNA interference to specifically knock down the expression of TRX1 with oligonucleotides encoding short-hairpin RNAs (Ti108: 108-130nt and Ti214: 214-236nt). We found that Ti214 could effectively down-regulate the expression of endogenous TRX1 (Figure 2A ). Treatment of Ti214-transfected HepG 2 cells with As 2 O 3 resulted in a significant increase of apoptosis compared with untreated control cells, although extensive down-regulation of TRX1 alone appeared to increase Annexin V positive cells ( Figure 2B ). Down-regulation of TRX1 also augmented As 2 O 3 -induced cyto c release ( Figure 2C ). These data suggest that TRX1 regulates the As 2 O 3 -induced apoptosis in HepG 2 cells, perhaps via regulation of mitochondrial cyto c release.
TRX1 over-expression inhibits As 2 O 3 -induced apoptosis in HepG 2 cells
TRX1 over-expression is observed in many human primary cancers and appears to contribute to increased cell growth and a resistance to chemotherapy [26] . To further examine the effects of TRX1 on As 2 O 3 -induced apoptosis, we constructed recombinant adenoviruses expressing the wild-type TRX1 and mutant TRX1 (cTm
C32/35S
) in which cysteine residues in the active site were changed to serine residues (see Figure 3A) . We then analyzed the sensitivity of transfected HepG 2 cells to As 2 O 3 -induced apoptosis and found that over-expression of wild-type TRX1 could inhibit As 2 O 3 -induced apoptosis ( Figure 3B apoptosis in APL cell lines [27, 28] , we measured cyto c release and found that TRX1 could prevent cyto c release induced by As 2 O 3 , whereas Tm C32/35S lost its protective effect. Actually, the mutant form of TRX1 enhanced the cyto c release from mitochondria ( Figure 3C ).
We next transiently transfected HepG 2 cells with pcDNA3.1/Myc-His, recombinant pCDNA3.1-TRX1 and pCDNA3.1-Tm
, and found that over-expression of wild-type TRX1 inhibited As 2 O 3 -induced caspase activation. In sharp contrast, over-expression of the mutant form 
Tm
C32/35S enhanced caspase activation ( Figure 3E ). Taken together, these studies suggest that TRX1 regulates As 2 O 3 -induced apoptosis, at least in part, by a mechanism that involves its active site.
TRX1 prevents mitochondria-related apoptotic changes induced by As 2 O 3 , while TRX1 mutant promotes the changes in vitro
We next investigated the molecular mechanisms of how TRX1 regulates As 2 O 3 -induced apoptosis in its active site-dependent fashion. The recombinant human TRX1 (rTRX1) and its mutant (rTm
C32/35S
) protein were expressed and purified, and these proteins were then used to treat the isolated mitochondria from mouse liver in the presence or absence of As 2 O 3 . In most cases 5 µM As 2 O 3 was used, but in certain experiments, as indicated, to avoid potential damage to the mitochondria due to the prolonged exposure, higher dose (40 µM) and shorter duration of treatments pSilencer-Ti214
pSilencer-Ti214
Annexin V-FITC were applied. As expected, we found that rTRX1 could potently protect isolated mitochondria from swelling, an indicator of mPTP opening, induced by As 2 O 3 ( Figure 4A , traces c and d). As 2 O 3 elicits the disruption of mitochondrial membrane potential, which is inhibited by rTRX1 ( Figure 4B Time (h) Figure 4E , panel right), whereas rTm
enhanced cyto c release in a dose-dependent manner ( Figure  4E, panel left) . Interestingly, rTm C32/35S alone, but not other mutant forms (C62S, C69S, and C73S, data not shown), induced cyto c release. These results further suggest that wild-type TRX1 may negatively regulate As 2 O 3 -induced apoptosis through the mitochondrial apoptotic pathway. Mutation of two cysteine residues to serine alters TRX1 function as assayed in mitochondria, suggesting that the redox activity of TRX1 is important for the regulation of As 2 O 3 -induced apoptosis.
Recombinant Tm C32/35S enhances ROS production and NAD(P)H oxidation in mitochondria
We next addressed how rTm C32/35S promotes mitochondrial changes. One possibility is that rTm C32/35S could translocate to mitochondria and perturb mitochondrial physiology, leading to mitochondrial dysfunction. It is well known that mitochondria are the major sources of superoxide and hydrogen peroxide in cells. Hence we examined whether rTRX1 and rTm C32/35S could target mitochondria. Following the incubation of isolated mitochondria with recombinant TRX1 and rTm
C32/35S
, both rTRX1 and rTm C32/35S could be detected in mitochondrial membrane fractions ( Figure 5A ). We further examined the effects of rTm C32/35S on ROS production in isolated mitochondria. We used dischlorofluorescein (DCFH) to measure ROS production in mitochondrial matrix and found that rTm C32/35S increased the rate of ROS generation in isolated mitochondria, which was inhibited by recombinant Bcl-xL protein ( Figure 5B ) and CsA (data not shown). The levels of ROS were measured in the presence of succinate, so it is possible that ROS were produced by complex III in the respiratory chain, where the ratio of the reduced form versus oxidized form of NAD(P)H is an indicator of the redox potential in mitochondria. We thus examined the effects of rTm C32/35S on oxidation of NAD(P)H and found that rTm C32/35S induced NAD(P)H oxidation in mitochondria. Interestingly, we found that Bcl-xL potently inhibited the oxidation reaction ( Figure 5C ). These results suggest that rTm C32/35S may promote apoptosis through changing the mitochondrial redox balance, resulting in mPTP opening and cyto c release.
Oxidation of TRX1 abolishes the inhibitory effects of TRX1 on As 2 O 3 -induced apoptosis
Our above results suggest that the redox status of TRX1 is important to its function. It had been reported that, in the presence of oxidant, the active site loop forms part of the dimer interface and the activity of TRX1 may thus be blocked [29] . To confirm this, firstly, we used diamide as an oxidant to treat purified rTRX1 and observed the existent 
2,4-Dinitrochlorobenzene (DNCB) elicits the oxidization of TRX1, induces apoptosis and increases the sensitivity of HepG 2 cells to As 2 O 3 -induced apoptosis
Thioredoxin reductase (TR) is important for maintaining the reduced form of TRX1 in cells, and the inhibition of TR prevents the conversion of oxidized TRX1 into reduced form [30, 31] . We found that As 2 O 3 could inhibit TR activity (data not shown), which is consistent with a previous report [32] . We treated HepG 2 cells with As 2 O 3 , DNCB (a specific inhibitor of TRX reductase) alone or the combination of both, then analyzed the redox status of TRX1 through nonreducing SDS-PAGE electrophoresis. Our results showed that TRX1 was oxidized by As 2 O 3 and DNCB treatments in a time-dependent manner. The combination of As 2 O 3 and DNCB induced significant increase in the oxidized [56] . Briefly, purified rTRX1 protein (1 µg/ml) was treated with or without 1 mM diamide, and was directly precipitated in 10% trichloroacetic acid (TCA). Precipitates were washed in 70% acetone and resuspended in 40 µl of reaction buffer (80 mM Tris-HCl, pH 6.8, 2% SDS) supplemented with a cocktail of protease inhibitors (Roche) and 15 mM freshly prepared AMS. Samples were incubated for 30 min at RT and for 10 min at 37 °C and then resolved by 15% SDS-PAGE. The redox state of TRX1 was detected by western blotting with anti-TRX1 antibody. (C) Isolated mitochondria were pre-incubated with 4 µg/ml oxidized rTRX1, then forms of rTRX1 through non-reducing SDS-PAGE electrophoresis. Diamide induced the oligomerization of rTRX1 in a dose-dependent manner ( Figure 6A ). Moreover, we found that the oligomerization of rTRX1 not only altered its redox status ( Figure. 6B ), resulting in a decrease of the reduced form of rTRX1, but also led to the loss of its ability to inhibit As 2 O 3 -induced swelling in isolated mitochondrial ( Figure 6C, trace c) , and the failure to protect against As 2 O 3 -induced mitochondrial cyto c release ( Figure 6D ). These results further support our notion that the regulation of As 2 O 3 -induced apoptosis by TRX1 is dependent on its active site. An inactive form elicited by oxidant fails to protect mitochondria from swelling and cyto c release initiated by As 2 O 3 . compared with control cells. The combination of both led to the greatest increase (11.5-fold) compared with control cells ( Figure 7B) . Moreover, the combination of As 2 O 3 and DNCB significantly increased cyto c release from mitochondria ( Figure 7C ), consistent with caspase activation in a time-dependent manner ( Figure 7D ). These data indicate that the inhibition of TR activity by DNCB results in the oxidization of TRX1, and subsequently facilitates 
Discussion
In this study, we showed the critical role of TRX1 in regulating As 2 O 3 -induced apoptosis. First, the expression level of TRX1 in cells is important for regulating cell death and drug sensitivity. Increased expression of wild-type TRX1 prevents HepG 2 cells from As 2 O 3 -induced apoptosis, while down-regulation of TRX1 with RNAi sensitizes the cells towards As 2 O 3 -induced apoptosis. Second, we found that the redox status of TRX1 determines the sensitivity of HepG 2 cells to As 2 O 3 treatment. Mutation of the active site cysteines in TRX1 enhanced As 2 O 3 -induced apoptosis. In vitro oxidization of TRX1 also caused a lost of protective function. To further support this notion, we found that DNCB, a specific inhibitor of TR, could induce TRX1 oxidation and significantly sensitized cells to As 2 O 3 -induced apoptosis. Previous studies have shown that arsenic can react with cysteine residues of GSH or TR to inactivate intracellular enzymes responsible for redox homeostasis [33, 34] . Our results also suggest a novel mechanism for sensitizing cancer cells to As 2 O 3 -induced apoptosis by modulating TRX1 redox status. This can be achieved either by inhibiting TR activity (Figure 7) or by direct reactions with cysteine residues within the TRX1 active site.
The redox status of TRX1 could also affect its interaction with ASK1, or other important molecules which mediate cell apoptosis [35] . However, our findings of this study suggest that mutation of the TRX1 active site cysteines could directly elicit destabilization of mitochondrial bioenergetics as well as cyto c release in the cells and isolated mitochondria, while wild-type TRX1 could prevent the apoptotic effects induced by both mutant TRX1 and As 2 O 3 . Direct application of the mutant form of TRX1 (C32S/35S), but not other mutant forms, to isolated mitochondria elicited the opening of mPTP, the loss of Δψ m , and subsequently the release of cyto c. Similarly, the oxidized form of TRX1 lost its function as an anti-apoptosis molecule and was able to enhance the apoptotic catastrophe of mitochondria. These effects appear to be direct in our in vitro system, without the involvement of cytosolic factors or signaling pathways as reported previously. Since TRX1 acts as one of the key components in the antioxidant system which antagonizes oxidative stress-induced apoptosis [35, 36] , our work supports that inactivation of TRX1 would confer a therapeutic advantage to cancer treatment by targeting mitochondria.
Questions remain regarding how inactivation or mutation of TRX1 directly elicits a mitochondria-related apoptotic response. We found that mutant TRX1 could disturb the redox potential of mitochondria as it caused the oxidation of mitochondrial NADH/NADPH and increased ROS production. This may subsequently perturb the mitochondrial redox pool of GSH and mtTRX2 (mitochondrial thioredoxin-2 (TRX2)), which are substrates of mitochondrial glutathione peroxidase and thioredoxin peroxidase, and thus decrease the capacity of these enzymes to remove H 2 O 2 . The perturbation of the redox pool may then globally modulate the mitochondria physiology, resulting in the opening of mPTP and increase of ROS production [37] . In addition, it has also been shown that cyto c that is released from mitochondria is a potent catalyst of DCFH oxidation [38] , and DCF fluorescence observed in the presence of rTm C32S/35S may be a reflection of increased cyto c content in the incubation buffer. This is unlikely in our system since this dye measured the ROS in the mitochondrial matrix.
To support these notions, we found that DTT, NADH, and ROS scavengers prevented rTm C32S/35S -induced mitochondria-related apoptotic changes (unpublished data). Another possibility is that the insertion of recombinant TRX1 proteins into the mitochondria and interactions with VDAC1 or other molecules modulate PTP activity for cyto c release.
Our results were consistent with a previous report which proved the interaction between TRX1 and VDAC1 [39] , since our pull-down assay showed that TRX1 could interact with VDAC1 in our system (data not shown). One report indicates that mitochondrial TRX2 might directly regulate cyto c release through the physical interaction with cyto c in mitochondria [40] . It remains to be determined if TRX1 can interact with cyto c.
In summary, our results indicate that TRX1 regulates As 2 O 3 -induced apoptosis by preventing mitochondrial cyto c release. Inactivation of TRX1 either by mutation of the active cysteine residues or by oxidation enhances mitochondria-dependent apoptosis induced by As 2 O 3 . Further studies are required to develop strategies to enhance the effect of As 2 O 3 therapy by modulating TRX1 activity in vivo.
Materials and Methods
Materials
Arsenic trioxide (A-1010) was purchased from Sigma (St. Louis, MO); 4-acetamido-4′-maleimidylstilbene-2,2′-disulfonic acid, disodium salt (AMS) (A-485), and anti-cyto c oxidase monoclonal antibody (subunit IV) were from Molecular Probes (Eugene, OR). ProBondTM metal affinity Resin was purchased from Invitrogen (San Diego, CA), and Amicon ® Ultra-15 concentrator was from Millipore (Billerica, MA). Anti-cyto c mouse monoclonal antibody was from BD Biosciences Pharmingen (San Jose, CA). Rabbit anti-human thioredoxin polyclonal IgG1 (sc-20146) was from Santa Cruz Biotechnology (Santa Cruz, CA). All other chemicals were purchased from Sigma (St. Louis, MO). tained in 1640 medium, both supplemented with 10% (v/v) fetal bovine serum (HyClone), 100 µg/ml streptomycin and 100 U/ml penicillin (HyClone) at 37 ºC in humidified 5% CO 2 atmosphere. Cell transfection was performed as described in the LIPOFECAMINE Reagent (GIBCO) manual.
Cell culture and transfection
Detection of cell death by Hoechst 33342 and Annexin-V-FITC
For Hoechst 33342 staining, cells were plated at low density on glass coverslides in a six-well plate and treated with 5 µM As 2 O 3 . After indicated time, cells were stained with Hoechst 33342 in PBS (15 min at room temperature in the dark). Cells were then washed three times with PBS and analyzed under a fluorescence microscope, and at least 200 cells were counted. Apoptotic cells were detected by flow cytometry. Phosphatidylserine exposed on the outside of the cells was determined by Annexin V-FITC kit. Briefly, HepG 2 cells were plated in six-well plates and treated with As 2 O 3 for the indicated time. At the end of the experiment, cells were digested with trypsin-EDTA solution, then collected by centrifugation and washed twice with ice-cold PBS. After being washed one more time with the incubation buffer (10 mM HEPES/NaOH, pH 7.4, 140 mM NaCl, and 5 mM CaCl 2 ), cells were stained with Annexin V-FITC and PI for 20 min in dark at room temperature; then an additional 400 µl binding buffer was added before FACS analysis [41] . Flow cytometric analysis was performed to monitor the green fluorescence of the FITC-conjugated Annexin V (530±30 nm) and the red fluorescence of DNA-bound PI (630±22 nm). All data were analyzed with Cell Quest software (BD).
SDS-PAGE and immunoblotting
SDS-PAGE and immunoblotting were performed as described elsewhere [42] . Briefly, the cells or membrane fractions were resuspended in NP-40 containing lysis buffer (10 mM HEPES (pH 7.4), 2 mM EGTA, 0.5% NP-40, 1 mM NaF, 1 mM NaVO 4 , 1 mM phenylmethylsulfonyl fluoride (PMSF), 1 mM DTT, 50 mg/ml trypsin inhibitor, 10 mg/ml aprotinin, and leupeptin) and placed on ice for 30 min. The lysates were centrifuged at 12 000×g for 12 min at 4 °C, and the protein concentration was determined with BSA as a standard. Equivalent samples (30 µg protein) were subjected to SDS-PAGE on 12% gel. The proteins were then transferred onto nitrocellulose membranes, and probed with the indicated antibodies followed by the appropriate secondary antibodies conjugated to horseradish peroxidase (KPL, Gaithersburg, MD, USA). Immunoreactive bands were visualized using enhanced chemiluminescence (Pierce). The molecular sizes of the developed proteins were determined by comparison with prestained protein markers (Invitrogen, Carlsbad, CA, USA).
Cell fractionation
As 2 O 3 -treated cells were fractionated by differential centrifugation as described previously [43] [44] [45] . Briefly, cells were harvested through trypsin digestion, and then centrifuged and resuspended in three volumes of hypotonic buffer (210 mM sucrose, 70 mM mannitol, 10 mM HEPES (pH 7.4), 1 mM EDTA) containing 1 mM PMSF, 50 mg/ml trypsin inhibitor, 10 mg/ml leupeptin, 5 mg/ml aprotinin and 10 mg/ml pepstatin. After gentle homogenization with a Dounce homogenizer, cell lysates were centrifuged at 1 000×g for 5 min to remove unbroken cells and nuclei and the cytosolic fractions were obtained by further centrifugation at 10 000×g for 30 min.
Generation of adenoviral recombinants and plasmids construction
The adenoviral recombinants of Ad-cTRX1 and Ad-cTm C32/35S were generated according to previous methods [46] . Briefly, PCR products (Bgl II + Not I) of TRX1 and its mutant were subcloned into pAdTrack-CMV shuttle vector. Recombinant adenoviral plasmids were generated by homologous recombination of recombinant shuttle vector linearized with PmeI and AdEasy-1 in BJ5183 Escherichia coli cells. Then, the recombinant adenovirus plasmids were linearized with PacI and then transfected into HEK293A cells to package recombinant virus. Virus propagation and amplification were then achieved by standard techniques.
To generate the over-expression of cTRX1 and cTm C32/35S vector, their cDNA fragments were subcloned into pCDNA3.1/myc-his vector and were confirmed by sequencing. In addition, to generate TRX1 RNAi vector, one annealed set of oligonucleotides encoding short-hairpin transcripts corresponding to nt 108-130 (named Ti108) and 214-236 (named Ti214) of human TRX1 mRNA (GenBank accession no. AF276919) were cloned into pSilencer-2.1-U6 (Ambion; hereafter abbreviated to pSilencer). In brief, the short-hairpin-RNAencoding complementary single-stranded oligonucleotides, which hybridized to give overhangs compatible with BamHI and HindIII, were designed with a computer program available on the internet http://www.ambion.com/techlib/misc/psilencer_converter.html. Oligonucleotides encoding short-hairpin RNAs were then ligated into pSilencer. The positive clones were confirmed by sequencing.
Expression and purification of recombinant proteins
The recombinant proteins were expressed and purified as described previously [47] . Briefly, His-tagged human TRX1 and Tm C32/35S were obtained through subcloning into the pET-28a (+). The resulting plasmids were transformed into E. coli BL21 (DE3). The positive transformants were induced for 4 h at 25 ºC by the addition of 1 mM isopropyl-b-D-thiogalactopyranoside (IPTG; Sigma). The induced cells were pelleted, resuspended in native binding buffer (20 mM sodium phosphate, 500 mM sodium chloride, pH 7.8), sonicated on ice, and centrifuged at 4 ºC for 30 min at 30 000×g to remove cell debris. The supernatants containing fusion proteins were purified with ProBond TM metal affinity resin and concentrated with Amicon ® Ultra-15 concentrators. The protein purity was verified by 12% SDS-PAGE and stained with Coomassie brillant blue R-250. The protein concentration was determined with BSA as a standard.
Isolation of mouse liver mitochondria and measurement of PTP opening and mitochondrial membrane potential (Δψ m )
Liver mitochondria from Balb/c mice were isolated by method as described previously [48] [49] [50] . Briefly, mice livers were homogenized with a glass-Teflon Potter homogenizer. Samples were centrifuged at 4 ºC, 1 000×g for 10 min. Then the supernatant was transferred to another tube and centrifuged at 4 ºC, 10 000×g for 10 min. Mitochondria were washed twice, then resuspended in the same medium. Isolated mitochondria (5 mg protein/ml) were kept in MT buffer containing 250 mM sucrose, 2 mM HEPES, pH 7.4, 0.1 mM EDTA, and 0.1% fatty acid-free BSA. PTP opening was monitored by the decrease of 90° light scattering at 520 nm at 25 ºC in medium PT-1 containing 250 mM sucrose, 2 mM HEPES, pH 7.4, 0.5 mM KH 2 PO 4 , 2 mM rotenone, and 4.2 mM potassium succinate, using a Jobin Yvon FluoroMax-2 spectrofluorimeter as described [51] . In addition, determination of mitochondrial membrane potential (Δψ m ) was performed as described previously [52, 53] . Briefly, after addition of 30 nM Rh123 to a mitochondria suspension, Dym was assessed at 25 ºC in medium PT-1 by measuring the uptake of Rh123 using a spectrofluorimeter (Jobin Yvon FluoroMax-2).
Assay of ROS production and determination of the NAD(P)H redox state
The generation of mitochondrial ROS was evaluated in isolated mitochondria in medium PT-1 using DCFH as a probe as described previously [54] . DCF formation was monitored using a Jobin Yvon FluoroMax-2 spectrofluorimeter. The oxidation of NAD(P)H in the mitochondria was measured at excitation and emission wavelengths of 350 and 450 nm as described [55] . All assays were carried out in triplicate.
Cyto c release and western blot analysis
Mouse liver mitochondria were isolated following the above method and protein content of isolated mitochondria was determined by the micro-biuret method using BSA as a standard. Equal mitochondria fractions were treated with different concentrations of rTm C32/35S at 25 ºC in PT-1 buffer for 60 min; in addition, 12 µg/ml rTRX1 was pre-incubated with mitochondria for 10 min, then 12 µg/ml rTm C32/35S and 40 µM arsenic trioxide was added and incubated for the same time. The samples were then centrifuged at 12 000×g for 15 min at 4 ºC. Cyto c resulting from the supernatant was detected by western blotting using anti-cyto c monoclonal antibody and visualized by ECL Supersignal system (Pierce), and equal protein loading was confirmed by immunodetection of cyto c oxidase subunit IV (COX-IV) in the mitochondrial pellets. The sample treated with 0.4 µM CaCl 2 was a positive control as indicated.
Detection of caspase activation in situ
The method was performed following the CaspACE TM FITC-VAD-FMK in situ Marker kit manual. Briefly, cells were digested with trypsin-EDTA solution, then collected and washed with PBS. CaspACE TM FITC-VAD-FMK In situ Marker was added to the cells at a final concentration of 10 µM, and then incubated for 20 min in the dark. Cells were washed three times with PBS, and resuspended in 400 µl PBS and measured with a FACScan.
Statistical analysis
Significant differences between values under different experimental conditions were determined by paired Student t test analyses. A value of P<0.05 was considered to be significant.
